Saturday 10 October 2026 Export all BMY data to Excel Powerpack

Bristol Myers Squibb Company

BMY Healthcare Drug Manufacturers General

Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 5.74%, EPS grew 153.1%, free cash flow fell 13.2% and total debt fell 12.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.

59.12 0.46 −0.77%

Follow BMY

Alert me

Market cap: $121.7B
P/E: 13.0×
Fwd P/E: 11.2×
Dividend yield: 4.26%
F-score: 8/9
Altman Z: 2.14
Beneish M: −2.69
Dividend safety: 63/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Insider Decisions trades per month

Total sells 2.29

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	1	—	—	—	1	1	—

Insider Ownership 0.10%

Capital & Financial Ratios $m

Market Cap 121,700.00

Revenue 49,186.00

Net Income 9,274.00

Free Cash Flow 11,440.00

Net Debt 32,053.00

Current Ratio 1.53

Debt/Equity 1.93

P/E ratio 13.02

Fwd P/E 11.20

P/S ratio 2.45

P/B ratio 5.41

Past 5Y EPS Growth —

This Y EPS Growth 13.13%

Next Y EPS Growth (5.04%)

Next Y revenue growth 3.48%

Next 5Y EPS Growth (3.23%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 6.40%

10-year low 10-year high

P/S against its own 10 years 20.86%

10-year low 10-year high

P/B against its own 10 years 52.29%

10-year low 10-year high

EV/Sales against its own 10 years 18.39%

10-year low 10-year high

EV/FCF against its own 10 years 48.74%

10-year low 10-year high

Dividends

Payout Ratio 0.56

Annual Dividend Rate 2.52

Annual Dividend Yield 4.26%

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	2.52	0.63 0.63 0.63 0.63
2025	2.48	0.62 0.62 0.62 0.62
2024	2.40	0.60 0.60 0.60 0.60
2023	2.28	0.57 0.57 0.57 0.57
2022	2.16	0.54 0.54 0.54 0.54
2021	1.47	0.49 0.49 0.49
2020	2.29	0.45 0.45 0.45 0.45 0.49
2019	1.64	0.41 0.41 0.41 0.41
2018	1.60	0.40 0.40 0.40 0.40
2017	1.56	0.39 0.39 0.39 0.39
2016	1.14	0.38 0.38 0.38

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	12,280	10,859	10,673	11,067
Receivables	10,921	10,747	11,414	10,553
Inventory	2,662	2,557	2,690	2,737
Other	5,907	5,617	4,613	4,222
	31,770	29,780	29,390	28,579

	2023	2024	2025	Q'26
Payables	3,259	3,602	3,575	4,158
ST’ Debt	3,119	2,046	2,261	1,027
Other	15,884	18,126	17,581	13,474
	22,262	23,774	23,417	18,659

Compound Annual Growth %

	10y	5y	3y
Sales	11.27%	2.54%	1.45%
Cash Flow	21.00%	0.15%	2.71%
Earnings	16.25%	0.00%	3.69%
Book Value	2.52%	(13.35%)	(15.91%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	11,489	12,973	—	—	—
’25	11,201	12,269	12,222	12,502	48,194
’24	11,865	12,201	11,892	12,342	48,300
’23	11,337	11,226	10,966	11,477	45,006
’22	11,648	11,887	11,218	11,406	46,159
’21	11,073	11,703	11,624	11,985	46,385
’20	10,781	10,129	10,540	11,068	42,518

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	1,104	3,393	—	—	—
’25	1,954	3,917	6,311	1,974	14,156
’24	2,834	2,326	5,591	4,439	15,190
’23	2,970	1,887	4,751	4,252	13,860
’22	3,812	2,261	3,687	3,306	13,066
’21	3,824	3,060	5,266	4,057	16,207
’20	3,937	4,493	2,267	3,355	14,052

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	757	3,088	—	—	—
’25	1,694	3,556	5,991	1,604	12,845
’24	2,550	2,064	5,267	4,061	13,942
’23	2,692	1,628	4,409	3,922	12,651
’22	3,559	1,989	3,440	2,960	11,948
’21	3,651	2,850	4,996	3,737	15,234
’20	3,751	4,362	2,114	3,072	13,299

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	1.31	1.62	—	—	—
’25	1.20	0.64	1.08	0.53	3.46
’24	(5.89)	0.83	0.60	0.04	(4.41)
’23	1.07	0.99	0.93	0.87	3.86
’22	0.59	0.66	0.75	0.95	2.95
’21	0.89	0.47	0.69	1.07	3.12
’20	(0.34)	(0.04)	0.82	(4.45)	(3.99)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	49.03	46.01	46.94	42.48	45.76	53.22	60.86	48.25	39.35	42.52	Analyst estimates 2026–2028 Powerpack
	High	77.12	66.10	70.05	64.75	68.34	69.75	81.44	75.18	61.08	63.33
People
People	Employees	25,000	23,700	23,300	30,000	30,250	32,200	34,300	34,100	34,100	32,500
	Revenue/emp, $m	0.78	0.88	0.97	0.87	1.41	1.44	1.35	1.32	1.42	1.48
Income, $m
Income, $m	Revenue	19,427	20,776	22,561	26,145	42,518	46,385	46,159	45,006	48,300	48,194
	Gross margin, %	74.42	71.05	71.34	69.10	72.31	78.57	78.04	76.24	71.08	71.08
	EBT	5,915	5,131	5,968	4,975	(6,871)	8,098	7,713	8,440	(8,379)	9,328
	EBT margin, %	30.45	24.70	26.45	19.03	(16.16)	17.46	16.71	18.75	(17.35)	19.36
	Net income	4,507	975	4,947	3,460	(8,995)	7,014	6,345	8,040	(8,933)	7,055
	Depreciation	382	789	637	1,746	10,380	10,686	10,276	9,760	9,600	4,011
Per share, $
Per share, $	Revenue	11.63	12.63	13.82	15.33	18.83	20.88	21.67	21.75	23.83	23.69
	Earnings	2.67	0.61	3.03	2.02	(3.99)	3.15	2.97	3.88	(4.41)	3.47
	Cash flow	1.83	3.21	4.33	4.82	6.22	7.30	6.13	6.70	7.49	6.96
	Capex	(0.73)	(0.64)	(0.58)	(0.49)	(0.33)	(0.44)	(0.52)	(0.58)	(0.62)	(0.64)
	Free cash flow	1.10	2.57	3.74	4.32	5.89	6.86	5.61	6.11	6.88	6.32
	Book value	9.78	7.20	8.65	30.32	16.78	16.21	14.61	14.25	8.08	9.10
	Shares, m	1,671	1,645	1,633	1,705	2,258	2,221	2,130	2,069	2,027	2,034
Valuation, ×
Valuation, ×	P/E	22.27	100.51	17.16	29.05	0.00	19.79	24.25	13.60	0.00	15.59
	P/S	5.11	4.85	3.76	4.19	3.29	2.99	3.33	2.43	2.37	2.28
	P/B	6.08	8.51	6.01	2.12	3.70	3.85	4.95	3.70	7.00	5.93
	EV/Sales	5.13	4.91	3.70	5.38	4.11	3.58	3.99	3.04	3.18	2.99
	EV/FCF	54.10	24.17	13.65	19.09	13.15	10.90	15.40	10.80	11.01	11.22
Cash, $m
Cash, $m	Operating cash flow	3,058	5,275	7,066	8,210	14,052	16,207	13,066	13,860	15,190	14,156
	Capex	(1,215)	(1,055)	(951)	(836)	(753)	(973)	(1,118)	(1,209)	(1,248)	(1,311)
	Free cash flow	1,843	4,220	6,115	7,374	13,299	15,234	11,948	12,651	13,942	12,845
Balance, $m
Balance, $m	Working capital	4,863	5,291	7,062	11,050	11,112	11,394	5,383	9,508	6,006	5,973
	Total debt	6,708	7,962	7,349	46,733	50,676	44,553	39,320	39,772	49,649	45,111
	Net debt	358	1,150	(1,410)	31,340	34,845	27,587	30,067	27,492	38,790	34,438
	Shareholders’ equity	16,347	11,847	14,127	51,698	37,882	36,006	31,118	29,485	16,388	18,506
Returns, %
Returns, %	ROA	13.62	2.99	14.36	4.17	(7.26)	6.14	6.14	8.36	(9.53)	7.72
	ROIC	22.13	24.67	29.33	3.74	(5.90)	7.96	7.88	9.26	(9.49)	11.01
	ROE	28.97	7.14	37.88	10.45	(20.13)	18.93	18.85	26.48	(39.01)	40.43

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NVS Novartis AG	$262.0B	21.6×	20.6×	+0.78% (above 0%: growing)	−17.39% (below 0%: shrinking)	−15.53% (below 0%: shrinking)	75.19%	31.77%	Compare
AZN AstraZeneca PLC	$246.3B	23.6×	23.4×	+6.41% (above 0%: growing)	+1.90% (above 0%: growing)	−107.45% (below 0%: shrinking)	83.60%	20.57%	Compare
AMGN Amgen Inc.	$220.3B	25.6×	22.7×	+9.53% (above 0%: growing)	+65.41% (above 0%: growing)	+82.57% (above 0%: growing)	72.04%	34.95%	Compare
GILD Gilead Sciences, Inc.	$182.4B	— (loss-making)	— (loss-making)	+10.18% (above 0%: growing)	n/m	+376.81% (above 0%: growing)	79.76%	(133.21%)	Compare
PFE Pfizer Inc.	$158.6B	37.2×	12.2×	+2.60% (above 0%: growing)	n/m	+125.17% (above 0%: growing)	72.78%	20.38%	Compare
NVO Novo Nordisk A/S	$127.8B	9.4×	—	+4.47% (above 0%: growing)	−18.68% (below 0%: shrinking)	+71.57% (above 0%: growing)	78.21%	34.48%	Compare
BMY Bristol Myers Squibb Company	$121.7B	13.0×	11.2×	+5.74% (above 0%: growing)	+153.13% (above 0%: growing)	−13.16% (below 0%: shrinking)	71.28%	31.50%
SNY Sanofi	$95.9B	21.0×	—	+17.35% (above 0%: growing)	−90.76% (below 0%: shrinking)	−45.06% (below 0%: shrinking)	75.47%	17.48%	Compare
GSK GSK PLC Sponsored ADR	$93.2B	14.5×	12.4×	+5.81% (above 0%: growing)	−69.47% (below 0%: shrinking)	+54.83% (above 0%: growing)	73.05%	5.72%	Compare
Median of peers	$170.5B	21.6×	20.6×	+6.11%	−18.03%	+63.20%	75.33%	20.48%

All 21 Drug Manufacturers General stocks →

Bristol Myers Squibb Company (BMY) key facts

Bristol Myers Squibb Company (BMY) is a Drug Manufacturers General company in the Healthcare sector, listed on the New York Stock Exchange.
Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024.
As of October 9, 2026, BMY traded at $59.12, a market capitalization of $121.7 billion.
Bristol Myers Squibb Company pays an annual dividend of $2.52 per share, a yield of 4.26%, with a payout ratio of 55.5%.
Return on equity was 40.4% and debt-to-equity 1.93.
Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 2.14 (grey zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.